Iovance reports 50% ORR with durable lifileucel monotherapy in advanced soft tissue sarcomas at ESMO 2026

Iovance Biotherapeutics reported a 50% objective response rate with lifileucel monotherapy in advanced soft tissue sarcomas (UPS and DDLPS) at ESMO 2026, with all responses ongoing at the time of presentation.

Detected & updated continuously · Source: Nebula